1. Pink Sheet
  2. >>Agency Leadership

US HHS Nominee Becerra Treading Carefully On ‘March In’ Rights

 
• By Michael McCaughan

Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.

shutterstock-1070395178 Washington, D.C., USA - April 14, 2018 The Jaguar Pride Marching Band of Blue Springs South High School going down the road in the 2018 National Cherry Blossom Parade
PhRMA's not exactly striking up the band about Becerra becoming HHS Secretary, but his statements during the confirmation hearings didn't hit too many sour notes. • Source: Shutterstock

US Department of Health & Human Services nominee Xavier Becerra’s two days of confirmation hearings did not shed a lot of light on specific policies he might implement on drug pricing – but they did provide some reassurance to biopharma companies concerned about his past support for so-called “march in” rights.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.